nm23-H1基因在子宫内膜癌中的表达及其与临床预后的相关性研究

目的 研究ｎｍ２３－Ｈ１基因在子宫内膜癌中的表达,探讨其与了宫内膜癌临床各参数之间的相关性,了解ｎｍ２３－Ｈ１基因对子宫内膜癌预后的影响。方法 采用免疫组化染色链霉素亲合素生物素标记法（ＬＳＡＢ）检测子宫内膜癌６０例。结果 ｎｍ２３－Ｈ１基因在６０例子宫内膜癌中的阳性表达率为５５．０％。

The expression of nm23-H1 genes with clinical prognosis in endometrial carcinoma

Objective To study the expression of nm23H1 gene in endometrial carcinoma and its relationships between the clinicopathological parameter and prognosis of endometrial carcinoma. Methods The endometril specimens of 60 cases with endometrial carcinoma were studied retrospectively by immunohistochemical stainings. Results The positive expression rate of nm23H1gene in endometrial carcinoma was 55.0%(33/60). The positive rate of nm23H1 in early endometrial carcinoma was significantly higher than that in advanced cases (65.9% and 25.0%, respectively, P<0.05). Positive rates in the well and moderately differentiated endometrial carcinoma were also higher than those of poorly differentiated (66.7%, 63.6%, 29.4%, P<0.05). 20.0% of the cases with and 64.9% of the cases without lymph node metastasis showed positive for nm23H1 (P<0.05). The expression of nm23H1 was not correlated with histological typemyometrial invasion estrogen receptor and progesterone receptor . The survival rate of patients with nm23H1 expression was significantly higher than that of patients without nm23H1expression. The 5year survival rate was 90.5% and 55.3% respectively (P<0.05). Conclusion nm23H1 gene may play a role in the inhibitory effect on the development and the lymph node metastasis of endometrial carcinoma , and may be related to be prognosis of endometrial carcinoma.